
Please try another search
PHAXIAM Therapeutics S.A., a clinical-stage biopharmaceutical company, focuses on developing bacteriophage-based therapies for severe resistance infections in France. The company develops and commercializes red cell-based therapies for cancers and orphan diseases. It develops anti-infectious therapies based on the use of bacteriophages (phages) to treat infections caused by Escherichia coli (E.coli), Pseudomonas aeruginosa (P.aeruginosa), and Staphylococcus aureus (S.aureus). The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. The company was incorporated in 2004 and is headquartered in Lyon, France.
Name | Age | Since | Title |
---|---|---|---|
Leila Nicolas | - | 2023 | Independent Director |
Didier Hoche | - | 2023 | Independent Director |
Philippe Archinard | 66 | 2013 | Independent Director |
Eric Raymond | - | 2009 | Consultant & Member of Scientific Board |
Philip L. Lorenzi | - | 2010 | Consultant & Member of Scientific Board |
Bridget Bax | - | 2012 | Consultant & Member of Scientific Board |
Gil Beyen | 63 | 2013 | Vice Chairman |
Arthur E. Frankel | - | 2012 | Consultant & Member of Scientific Board |
Kurt C. Gunter | 70 | 2012 | Consultant & Member of Scientific Board |
Hilde Windels | 60 | 2014 | Independent Director |
Robert Sebbag | 74 | 2023 | Independent Director |
Valerie Faillat | - | 2024 | Independent Director |
Guy Rigaud | 78 | 2023 | Board Censor |
Olivier Martinez | 52 | 2024 | Board Censor |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review